Bad Soden am Taunus, Germany

Rudolf Bender


Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 145(Granted Patents)


Location History:

  • Kronberg, DE (1986)
  • Bad Soden am Taunus, DE (1995 - 2002)

Company Filing History:


Years Active: 1986-2002

Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Rudolf Bender: Innovator in Quinoxaline Patents**

Introduction

Rudolf Bender is a distinguished inventor hailing from Bad Soden am Taunus, Germany. With a remarkable portfolio of four patents, Bender has made significant contributions to the field of chemistry, particularly in the development of quinoxalines that exhibit antiviral properties.

Latest Patents

Among Rudolf Bender's latest patents are groundbreaking works titled "Quinoxalines, processes for their preparation and their use" and "Azaquinoxalines and their use." His research has led to the identification of compounds that display an effect against viruses, showcasing the innovative potential of his findings. Notably, these patents describe compounds of specific formulas that have promising applications in antiviral drugs.

Career Highlights

Rudolf Bender has had a noteworthy career, including significant positions at renowned companies such as Hoechst Aktiengesellschaft and Hoeschst Aktiengesellschaft. His work at these organizations has allowed him to develop his ideas and contribute to the advancement of chemical sciences.

Collaborations

Throughout his career, Bender has collaborated with esteemed colleagues, including Laszlo Vertesy and Hans-Wolfram Fehlhaber. These collaborations have played an essential role in enhancing his research and expanding the impact of his innovations in the pharmaceutical field.

Conclusion

With a robust background in chemistry and a keen focus on antiviral applications, Rudolf Bender continues to be an influential figure in the world of patents and innovations. His contributions to quinoxaline research underscore the vital role inventors play in advancing scientific knowledge and developing new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…